Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

Rhea-AI Summary

Neuphoria Therapeutics (Nasdaq: NEUP), a clinical-stage biotech company focused on neuropsychiatric treatments, announced its upcoming presentation at the ASCP 2025 Annual Meeting. The company's President and CEO, Dr. Spyros Papapetropoulos, will present a pharmacokinetic/pharmacodynamic analysis of the BNC210 Attune Phase 2b dataset, which will help determine dosing for a planned Phase 3 PTSD study. The presentation is scheduled for May 28, 2025, from 3:40-4:00 pm MST at the Fairmont Scottsdale Princess in Arizona.

BURLINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced an upcoming presentation at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting.

Presentation details:

• Title: Pharmacokinetic/Pharmacodynamic Analysis of the BNC210 Attune Phase 2b Dataset Enables Dose Selection for Planned Phase 3 PTSD Study
• Presenter: Spyros Papapetropoulos, M.D., Ph.D., Neuphoria President and CEO
• Type: Oral presentation
• Location: ASCP 2025 Annual Meeting, Fairmont Scottsdale Princess Salon Ballroom H, Scottsdale, AZ
• Session: Individual research reports
• Date: Wednesday, 28^th May, 2025
• Time: 3:40-4:00 pm MST
  
  

FOR FURTHER INFORMATION PLEASE CONTACT:

General Spyridon (Spyros) Papapetropoulos info@neuphoriatx.com	Investor Relations Kevin Gardner kgardner@lifesciadvisors.com

About Neuphoria Therapeutics Inc.
Neuphoria (Nasdaq: NEUP) is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, “as needed” treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD). BNC210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, Neuphoria has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Neuphoria's pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.

Forward-Looking Statements
Neuphoria cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs, plans, burn rate and expectations. Certain forward-looking statements, including (without limitation) about (1) Neuphoria’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement and/or completion of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Neuphoria’s financial resources, and (4) assumptions underlying any such statements. The inclusion of forward-looking statements should not be regarded as a representation by Neuphoria that any of its plans will be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors.   Certain forward-looking statements involve contracts, licenses and arrangements involving third parties and their respective clinical trial and research and development projects that are out of our control, including our agreements with Merck and Carina. They may terminate or delay any or all such projects in their discretion pursuant to the terms of our agreements with them, which could result in the Company not realizing any further milestone payments or further progress on the respective product pathways. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K, Quarterly Report on Form 10-Q, each filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Neuphoria undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks, uncertainties and other factors is included in Neuphoria’s filings with the SEC, copies of which are available from the SEC’s website (www.sec.gov) and on Neuphoria’s website (www.neuphoriatx.com) under the heading “Investor Center.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Neuphoria expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

FAQ

What will Neuphoria (NEUP) present at the ASCP 2025 Annual Meeting?

Neuphoria will present a pharmacokinetic/pharmacodynamic analysis of the BNC210 Attune Phase 2b dataset, which will help determine dosing for their planned Phase 3 PTSD study.

When and where is Neuphoria's (NEUP) presentation at ASCP 2025?

The presentation will take place on Wednesday, May 28, 2025, from 3:40-4:00 pm MST at the Fairmont Scottsdale Princess Salon Ballroom H in Scottsdale, Arizona.

Who will be presenting for Neuphoria (NEUP) at the ASCP 2025 Meeting?

Dr. Spyros Papapetropoulos, Neuphoria's President and CEO, will deliver the presentation.

What is the current development stage of Neuphoria's (NEUP) BNC210 drug?

BNC210 has completed Phase 2b trials and is preparing for Phase 3 studies in PTSD treatment.